8-K: Verrica Pharma Q3 2026: YCANTH Revenue Surges, Pipeline Advances

Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, up 57.9% year-over-year, while advancing its common warts Phase 3 trials and exploring new indications for VP-315.

Summary

• Verrica Pharmaceuticals announced its third quarter and nine months ended September 30, 2026 financial results.
• The company reported record U.S. YCANTH net product revenue of $5.7 million for Q3 2026, an increase of 11.9% from the previous quarter and 57.9% year-over-year.
• Total revenue for Q3 2026 was $6.9 million, compared to $14.3 million in Q3 2025, which included a $10.0 million milestone payment.
• Enrollment is complete for the first of two pivotal Phase 3 trials for YCANTH in common warts, with topline data expected in Q1 2027 and mid-2027.
• The company achieved milestones to unlock the full $27.5 million credit facility, extending its cash runway through the common warts trial data readouts.
• Verrica is exploring the development of its oncolytic peptide, VP-315, for Gorlin syndrome.
• Net loss for Q3 2026 was $12.4 million ($0.58 per share), compared to a net loss of $0.3 million ($0.03 per share) in Q3 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong YCANTH revenue growth and pipeline progress, balanced by ongoing net losses and increased R&D expenses.

Positives

• Record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% sequentially and 57.9% year-over-year.
• Total revenue of $6.9 million in Q3 2026, driven by strong YCANTH product sales.
• Completion of enrollment in the first pivotal Phase 3 trial for YCANTH in common warts.
• Over 50% enrollment in the second pivotal Phase 3 trial for YCANTH in common warts.
• Achieved milestones to unlock the full $27.5 million credit facility, providing non-dilutive growth capital.
• Cash runway extended through data readouts for both common warts pivotal trials.
• Exploring VP-315 for Gorlin syndrome, a rare disease with no current FDA-approved products.
• YCANTH dispensed applicator units increased approximately 36% year-over-year in Q3 2026.

Negatives

• Total revenue decreased to $6.9 million in Q3 2026 from $14.3 million in Q3 2025, primarily due to the absence of a $10.0 million milestone payment in the current year.
• Net loss for Q3 2026 was $12.4 million, a significant increase from the $0.3 million net loss in Q3 2025.
• Selling, general and administrative expenses increased to $10.4 million in Q3 2026 from $9.4 million in Q3 2025.
• Research and development expenses significantly increased to $7.6 million in Q3 2026 from $2.2 million in Q3 2025, largely due to the common warts Phase 3 program.
• Sequential decrease of approximately 2.5% in YCANTH dispensed applicator units from the prior quarter, attributed to summer seasonality.
• Stockholders' deficit of $5.974 million as of September 30, 2026.

Risks

• The company's ability to successfully complete and obtain positive results from its Phase 3 trials for YCANTH in common warts.
• The potential for actual results of clinical trials to differ from management's expectations.
• Market conditions and other risks and uncertainties described in Verrica's SEC filings.
• The potential for delays in regulatory filings or approvals for YCANTH in common warts or VP-315 for Gorlin syndrome.
• Competition in the dermatological disease market.
• The company's ability to manage its cash runway and secure future funding if needed beyond current projections.
• The success of the commercialization of YCANTH for molluscum contagiosum and potential future indications.
• The exploration of VP-315 for Gorlin syndrome involves evaluating study design and trial budgets, with potential costs not currently factored into the cash runway.

Future Outlook

The company expects topline data from its two pivotal Phase 3 trials for YCANTH in common warts in Q1 2027 and mid-2027, respectively. With the full utilization of its credit facility, Verrica believes it has sufficient liquidity to fund operations through these data readouts. The company is also exploring the development of VP-315 for Gorlin syndrome, with further details on study design and timelines to be provided.

Management Comments

• "YCANTH had another record quarter for revenue, and we are now turning our focus to maximize conversion of written to filled prescriptions and ensuring optimal insurance coverage."
• "We are also executing on our label expansion strategy for YCANTH into common warts."
• "Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program."
• "With a prevalence of approximately 22 million patients in the U.S. alone and no FDA-approved prescription drug therapies, we believe that securing a label expansion for YCANTH into common warts could represent a multibillion-dollar commercial opportunity, if approved."
• "Finally, we are now exploring the potential of VP-315 to treat patients with Gorlin syndrome, a rare disease that leads to dozens or hundreds of basal cell carcinomas over the patients lifetime, often presenting them with substantial surgical fatigue."
• "We are excited about our future at Verrica, having built a solid commercial foundation to support promotion of YCANTH for molluscum which we can leverage upon any approval of YCANTH for common warts or VP-315 for BCC or Gorlin syndrome."

Industry Context

StockSavvy.ai notes that Verrica's progress aligns with the trend of pharmaceutical companies seeking label expansions for existing drugs into new indications, particularly for conditions with significant unmet needs like common warts. The exploration of VP-315 for Gorlin syndrome also reflects a growing interest in treatments for rare diseases.

Comparison to Industry Standards

• The year-over-year revenue growth for YCANTH of 57.9% is strong, particularly for a commercial-stage product in a niche dermatological market. However, direct comparisons are difficult without specific competitor revenue data for similar products.
• The significant increase in R&D expenses for the common warts Phase 3 program is typical for companies advancing late-stage clinical trials, which often represent a substantial portion of a biotech's operating costs.
• The net loss reported is common for clinical-stage and early commercial-stage biopharmaceutical companies investing heavily in pipeline development and commercialization efforts.

Related Party Transactions

• The company has a credit facility with an entity controlled by Paul B. Manning, the Company's Chairman and largest shareholder, under which $15.0 million was recently unlocked.

Stakeholder Impact

• Shareholders: The company's financial performance, pipeline progress, and extended cash runway are key factors influencing shareholder value. The increased net loss and R&D spending may be viewed with caution.
• Employees: Continued investment in R&D and commercialization suggests ongoing employment opportunities, but financial performance can impact job security.
• Creditors: The company has a credit facility with an affiliate of its Chairman, indicating a reliance on related party financing.
• Partners (e.g., Torii Pharmaceutical, Medomie Pharma): Progress in clinical trials and commercialization efforts for YCANTH directly impacts these partnerships.

Next Steps

• Continue to maximize conversion of written to filled prescriptions for YCANTH and ensure optimal insurance coverage.
• Advance the second pivotal Phase 3 trial for YCANTH in common warts, with over 50% enrollment achieved.
• Receive topline data from the first pivotal Phase 3 trial for YCANTH in common warts in Q1 2027.
• Receive topline data from the second pivotal Phase 3 trial for YCANTH in common warts in mid-2027.
• Finalize clinical protocol and anticipated timelines for VP-315 development for Gorlin syndrome.
• Support Medomie Pharma Ltd.'s regulatory filing for YCANTH in Israel.

Key Dates

Recommendation

Verrica Pharmaceuticals demonstrates strong commercial execution with YCANTH revenue growth and significant progress in its common warts pipeline. The extension of the cash runway through data readouts is positive. However, the substantial increase in net loss and R&D expenses, coupled with the inherent risks of late-stage clinical trials, warrants a 'hold' recommendation pending further clinical data and commercialization milestones.

Keywords

YCANTH, VP-102, molluscum contagiosum, common warts, VP-315, Gorlin syndrome, dermatology, Phase 3 trials